A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells

Ilana Chefetz, Edward Grimley, Kun Yang, Linda Hong, Ekaterina V. Vinogradova, Radu Suciu, Ilya Kovalenko, David Karnak, Cynthia A. Morgan, Mikhail Chtcherbinine, Cameron Buchman, Brandt Huddle, Scott Barraza, Meredith Morgan, Kara A. Bernstein, Euisik Yoon, David B. Lombard, Andrea Bild, Geeta Mehta, Iris RomeroChun Yi Chiang, Charles Landen, Benjamin Cravatt, Thomas Hurley, Scott D. Larsen, Ronald J. Buckanovich

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ovarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer “stemness,” and expression of the stem cell marker CD133. As such, ALDH activity has been proposed as a therapeutic target. Although it remains controversial which of the 19 ALDH family members drive chemotherapy resistance, ALDH1A family members have been primarily linked with chemotherapy resistant and stemness. We identified two ALDH1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially kills CD133 + ovarian cancer stem-like cells (CSCs). ALDH1Ai induce necroptotic CSC death, mediated, in part, by the induction of mitochondrial uncoupling proteins and reduction in oxidative phosphorylation. ALDH1Ai is highly synergistic with chemotherapy, reducing tumor initiation capacity and increasing tumor eradication in vivo. These studies link ALDH1A with necroptosis and confirm the family as a critical therapeutic target to overcome chemotherapy resistance and improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)3061-3075.e6
JournalCell Reports
Volume26
Issue number11
DOIs
StatePublished - Mar 12 2019

Fingerprint

Chemotherapy
Neoplastic Stem Cells
Ovarian Neoplasms
Aldehyde Dehydrogenase
Drug Therapy
Tumors
Neoplasms
Cell death
Stem cells
Oxidative Phosphorylation
Cell Death
Stem Cells
Therapeutics
Proteins

Keywords

  • ALDH
  • CD133
  • cell death
  • CSC
  • necroptosis
  • ovarian cancer
  • resistance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Chefetz, I., Grimley, E., Yang, K., Hong, L., Vinogradova, E. V., Suciu, R., ... Buckanovich, R. J. (2019). A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Reports, 26(11), 3061-3075.e6. https://doi.org/10.1016/j.celrep.2019.02.032

A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. / Chefetz, Ilana; Grimley, Edward; Yang, Kun; Hong, Linda; Vinogradova, Ekaterina V.; Suciu, Radu; Kovalenko, Ilya; Karnak, David; Morgan, Cynthia A.; Chtcherbinine, Mikhail; Buchman, Cameron; Huddle, Brandt; Barraza, Scott; Morgan, Meredith; Bernstein, Kara A.; Yoon, Euisik; Lombard, David B.; Bild, Andrea; Mehta, Geeta; Romero, Iris; Chiang, Chun Yi; Landen, Charles; Cravatt, Benjamin; Hurley, Thomas; Larsen, Scott D.; Buckanovich, Ronald J.

In: Cell Reports, Vol. 26, No. 11, 12.03.2019, p. 3061-3075.e6.

Research output: Contribution to journalArticle

Chefetz, I, Grimley, E, Yang, K, Hong, L, Vinogradova, EV, Suciu, R, Kovalenko, I, Karnak, D, Morgan, CA, Chtcherbinine, M, Buchman, C, Huddle, B, Barraza, S, Morgan, M, Bernstein, KA, Yoon, E, Lombard, DB, Bild, A, Mehta, G, Romero, I, Chiang, CY, Landen, C, Cravatt, B, Hurley, T, Larsen, SD & Buckanovich, RJ 2019, 'A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells', Cell Reports, vol. 26, no. 11, pp. 3061-3075.e6. https://doi.org/10.1016/j.celrep.2019.02.032
Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R et al. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Reports. 2019 Mar 12;26(11):3061-3075.e6. https://doi.org/10.1016/j.celrep.2019.02.032
Chefetz, Ilana ; Grimley, Edward ; Yang, Kun ; Hong, Linda ; Vinogradova, Ekaterina V. ; Suciu, Radu ; Kovalenko, Ilya ; Karnak, David ; Morgan, Cynthia A. ; Chtcherbinine, Mikhail ; Buchman, Cameron ; Huddle, Brandt ; Barraza, Scott ; Morgan, Meredith ; Bernstein, Kara A. ; Yoon, Euisik ; Lombard, David B. ; Bild, Andrea ; Mehta, Geeta ; Romero, Iris ; Chiang, Chun Yi ; Landen, Charles ; Cravatt, Benjamin ; Hurley, Thomas ; Larsen, Scott D. ; Buckanovich, Ronald J. / A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. In: Cell Reports. 2019 ; Vol. 26, No. 11. pp. 3061-3075.e6.
@article{4a0b21c23039452e8f11bc4b1cd14287,
title = "A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells",
abstract = "Ovarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer “stemness,” and expression of the stem cell marker CD133. As such, ALDH activity has been proposed as a therapeutic target. Although it remains controversial which of the 19 ALDH family members drive chemotherapy resistance, ALDH1A family members have been primarily linked with chemotherapy resistant and stemness. We identified two ALDH1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially kills CD133 + ovarian cancer stem-like cells (CSCs). ALDH1Ai induce necroptotic CSC death, mediated, in part, by the induction of mitochondrial uncoupling proteins and reduction in oxidative phosphorylation. ALDH1Ai is highly synergistic with chemotherapy, reducing tumor initiation capacity and increasing tumor eradication in vivo. These studies link ALDH1A with necroptosis and confirm the family as a critical therapeutic target to overcome chemotherapy resistance and improve patient outcomes.",
keywords = "ALDH, CD133, cell death, CSC, necroptosis, ovarian cancer, resistance",
author = "Ilana Chefetz and Edward Grimley and Kun Yang and Linda Hong and Vinogradova, {Ekaterina V.} and Radu Suciu and Ilya Kovalenko and David Karnak and Morgan, {Cynthia A.} and Mikhail Chtcherbinine and Cameron Buchman and Brandt Huddle and Scott Barraza and Meredith Morgan and Bernstein, {Kara A.} and Euisik Yoon and Lombard, {David B.} and Andrea Bild and Geeta Mehta and Iris Romero and Chiang, {Chun Yi} and Charles Landen and Benjamin Cravatt and Thomas Hurley and Larsen, {Scott D.} and Buckanovich, {Ronald J.}",
year = "2019",
month = "3",
day = "12",
doi = "10.1016/j.celrep.2019.02.032",
language = "English (US)",
volume = "26",
pages = "3061--3075.e6",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "11",

}

TY - JOUR

T1 - A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells

AU - Chefetz, Ilana

AU - Grimley, Edward

AU - Yang, Kun

AU - Hong, Linda

AU - Vinogradova, Ekaterina V.

AU - Suciu, Radu

AU - Kovalenko, Ilya

AU - Karnak, David

AU - Morgan, Cynthia A.

AU - Chtcherbinine, Mikhail

AU - Buchman, Cameron

AU - Huddle, Brandt

AU - Barraza, Scott

AU - Morgan, Meredith

AU - Bernstein, Kara A.

AU - Yoon, Euisik

AU - Lombard, David B.

AU - Bild, Andrea

AU - Mehta, Geeta

AU - Romero, Iris

AU - Chiang, Chun Yi

AU - Landen, Charles

AU - Cravatt, Benjamin

AU - Hurley, Thomas

AU - Larsen, Scott D.

AU - Buckanovich, Ronald J.

PY - 2019/3/12

Y1 - 2019/3/12

N2 - Ovarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer “stemness,” and expression of the stem cell marker CD133. As such, ALDH activity has been proposed as a therapeutic target. Although it remains controversial which of the 19 ALDH family members drive chemotherapy resistance, ALDH1A family members have been primarily linked with chemotherapy resistant and stemness. We identified two ALDH1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially kills CD133 + ovarian cancer stem-like cells (CSCs). ALDH1Ai induce necroptotic CSC death, mediated, in part, by the induction of mitochondrial uncoupling proteins and reduction in oxidative phosphorylation. ALDH1Ai is highly synergistic with chemotherapy, reducing tumor initiation capacity and increasing tumor eradication in vivo. These studies link ALDH1A with necroptosis and confirm the family as a critical therapeutic target to overcome chemotherapy resistance and improve patient outcomes.

AB - Ovarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer “stemness,” and expression of the stem cell marker CD133. As such, ALDH activity has been proposed as a therapeutic target. Although it remains controversial which of the 19 ALDH family members drive chemotherapy resistance, ALDH1A family members have been primarily linked with chemotherapy resistant and stemness. We identified two ALDH1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially kills CD133 + ovarian cancer stem-like cells (CSCs). ALDH1Ai induce necroptotic CSC death, mediated, in part, by the induction of mitochondrial uncoupling proteins and reduction in oxidative phosphorylation. ALDH1Ai is highly synergistic with chemotherapy, reducing tumor initiation capacity and increasing tumor eradication in vivo. These studies link ALDH1A with necroptosis and confirm the family as a critical therapeutic target to overcome chemotherapy resistance and improve patient outcomes.

KW - ALDH

KW - CD133

KW - cell death

KW - CSC

KW - necroptosis

KW - ovarian cancer

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85062674089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062674089&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2019.02.032

DO - 10.1016/j.celrep.2019.02.032

M3 - Article

C2 - 30865894

AN - SCOPUS:85062674089

VL - 26

SP - 3061-3075.e6

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 11

ER -